Effect of enamel matrix proteins on the treatment of intrabony defects: a split-mouth randomized controlled trial study.
The objective of this split-mouth, double-blind, randomized controlled trial was to compare the clinical effect of treatment of 2- or 3-wall intrabony defects with open flap debridement (OFD) combined or not with enamel matrix proteins (EMP). Thirteen volunteers were selected with one pair of or more intrabony defects and probing pocket depth (PPD) > or = 5 mm. All individuals received instructions regarding oral hygiene and were submitted to scaling and root planing. Each participant received the two treatment modalities: test sites were treated with OFD and EMP, and control sites received only OFD. After 6 months, a significant reduction was observed in PPD for the EMP group (from 6.42 +/- 1.08 mm to 2.67 +/- 1.15 mm) and for the OFD group (from 6.08 +/- 1.00 mm to 2.00 +/- 0.95 mm) (p < 0.0001), but with no significant difference between groups (p = 0.13). A significant gain in relative attachment level (RAL) was observed in both groups (EMP: from 13.42 +/- 1.88 mm to 10.75 +/- 2.26 mm, p < 0.001; OFD: from 12.42 +/- 1.98 mm to 10.58 +/- 2.23 mm, p = 0.013), but with no significant difference between groups (p = 0.85). Gingival recession (GR) was higher in the EMP group (from 1.08 +/- 1.50 mm to 2.33 +/- 1.43 mm; p = 0.0009) than in the OFD group (from 0.66 +/- 1.15 mm to 1.16 +/- 1.33 mm; p = 0.16), but this difference was not significant (p = 0.06). In conclusion, the results showed that OFD combined with EMP was not able to improve treatment of intrabony defects compared to OFD alone.
Chambrone
Daniela
D
Department of Stomatology, Division of Periodontics, School of Dentistry, University of São Paulo, Brazil. chambron@usp.br
Pasin
Ivan Munhoz
IM
Conde
Marina Clemente
MC
Panutti
Claudio
C
Carneiro
Silvia
S
Lima
Luiz Antonio Pugliesi Alves de
LA
D000328:Adult; D016301:Alveolar Bone Loss / Q000188:drug therapy* / Q000601:surgery*; D001861:Bone Regeneration / Q000187:drug effects*; D003131:Combined Modality Therapy / Q000379:methods; D003646:Debridement; D003746:Dental Enamel Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D003774:Dental Plaque Index; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005889:Gingival Recession / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D008297:Male; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000601:surgery; D013524:Surgical Flaps; D014092:Tooth Root / Q000187:drug effects
D003746:Dental Enamel Proteins; C109069:enamel matrix proteins